background
chronic
lung
allograft
dysfunct
clad
main
limit
longterm
surviv
lung
transplant
effect
therapi
lack
earli
identif
mitig
risk
factor
pragmat
approach
improv
outcom
acut
cellular
reject
acr
pervas
risk
factor
clad
diagnosi
requir
transbronchi
biopsi
carri
risk
hypothes
gene
express
bronchoalveolar
lavag
bal
cell
pellet
cp
could
replac
biopsi
inform
mechan
clad
method
perform
rna
sequenc
bal
cp
lung
transplant
recipi
agrad
acr
n
lymphocyt
bronchiol
n
infect
n
rejectioninfect
n
differenti
gene
express
base
absolut
fold
differ
benjaminiadjust
pvalu
use
databas
annot
visual
integr
discoveri
bioinformat
resourc
pathway
analys
classifi
model
sampl
randomli
split
train
n
test
set
n
logist
regress
model
use
recurs
featur
elimin
crossvalid
train
optim
area
curv
auc
result
differenti
gene
express
identifi
gene
enrich
pathway
includ
tcell
receptor
signal
natur
killer
cytotox
receptor
interact
model
auc
classif
threshold
defin
train
set
exhibit
fair
perform
test
set
accuraci
specif
sensit
addit
classif
acr
associ
wors
cladfre
surviv
hazard
ratio
confid
interv
lung
transplant
remain
viabl
treatment
option
select
patient
advanc
lung
diseas
longterm
outcom
remain
disappoint
main
limit
better
longterm
surviv
chronic
lung
allograft
dysfunct
clad
affect
half
lung
recipi
year
posttranspl
current
proven
effect
treatment
therefor
prevent
strategi
key
includ
risk
factor
identif
mitig
princip
risk
factor
clad
acut
reject
precis
agrad
acut
cellular
reject
acr
diagnos
transbronchi
biopsi
tbbx
exhibit
perivascular
mononuclear
cell
infiltr
extend
interstitium
although
definit
data
lack
wide
accept
treatment
agrad
acr
augment
immun
suppress
import
strategi
reduc
risk
clad
howev
unnecessari
treatment
increas
risk
opportunist
infect
malign
make
accur
diagnosi
import
airway
inflamm
also
known
lymphocyt
bronchiol
lb
variabl
also
term
bgrade
acr
howev
frequent
coexist
airway
infect
well
report
refractori
corticosteroid
treatment
sourc
controversi
inclus
lb
acr
although
consid
current
gold
standard
util
tbbx
diagnos
agrad
acr
limit
sever
factor
first
tbbx
associ
incid
pneumothorax
incid
major
bleed
lung
transplant
recipi
specif
incid
major
complic
bronchoscopi
tbbx
major
risk
factor
besid
patient
safeti
tbbx
associ
rel
high
rate
sampl
error
recent
multicent
studi
approxim
tbbx
yield
inadequ
sampl
unabl
grade
agrad
acr
anoth
assess
suboptim
fewer
piec
wellexpand
alveol
lung
even
alveol
tissu
obtain
affect
area
may
miss
rel
small
volum
tissu
sampl
tbbx
final
welldescrib
variabl
interobserv
interpret
tbbx
agrad
acr
k
valu
rang
furthermor
interobserv
agreement
bgrade
acr
lb
even
wors
k
valu
rang
limit
abil
safe
reliabl
diagnos
acr
may
affect
clinician
abil
mitig
risk
prevent
clad
bronchoalveolar
lavag
bal
routin
perform
concurr
tbbx
rule
infect
compar
tbbx
bal
safer
sampl
rel
larg
area
lung
hypothes
gene
express
bal
cell
pellet
cp
could
replac
tbbx
diagnosi
acr
improv
risk
stratif
progress
clad
particip
studi
provid
written
inform
consent
enrol
univers
california
lo
angel
ucla
lung
transplant
outcom
registri
biorepositori
approv
ucla
institut
review
board
studi
sponsor
clinic
trial
organ
transplant
ancillari
studi
grant
enrol
lung
transplant
recipi
ucla
lung
transplant
outcom
registri
biorepositori
studi
sinc
lung
recipi
ucla
undergo
surveil
bronchoscopi
month
posttranspl
clinic
indic
collect
bank
leftov
bal
fluid
surveil
caus
bronchoscopi
bal
procedur
perform
accord
standard
protocol
use
three
aliquot
isoton
salin
instil
subsegment
bronchu
either
right
middl
lobe
left
lingula
retriev
bal
fluid
pool
split
clinic
specimen
research
specimen
remain
volum
research
sampl
immedi
place
ice
transport
lab
process
within
hour
collect
bal
fluid
filter
steril
gauz
cell
separ
fluid
centrifug
cell
wash
twice
phosphatebuff
salin
lyse
trizol
invitrogen
carlsbad
ca
tbbx
specimen
grade
acr
experienc
thorac
pathologist
accord
standard
intern
societi
heart
lung
transplant
criteria
briefli
perivascular
agrad
infiltr
score
howev
pathologist
grade
periairway
infiltr
lb
bgrade
absent
present
center
adopt
revis
nomenclatur
bgrade
reject
specimen
use
studi
span
chang
nomenclatur
could
consid
lb
present
absent
biopsi
result
base
upon
chart
review
clinic
read
slide
rereview
agrad
acr
episod
also
categor
either
spirometr
signific
ssar
nonssar
base
declin
forc
expiratori
volum
one
second
fev
baselin
defin
highest
preced
fev
measur
describ
davi
et
al
agrad
acr
episod
without
pair
fev
measur
day
biopsi
could
classifi
ssar
nonssar
clad
defin
sustain
drop
fev
least
averag
best
posttranspl
measur
consist
publish
criteria
potenti
clad
case
review
avail
clinic
data
exclud
altern
caus
fev
declin
clad
search
biorepositori
bal
cp
sampl
collect
diagnosi
clad
patient
never
develop
clad
pair
tbbx
grade
aand
bgrade
reject
score
preclad
sampl
repositori
pair
tbbx
exclud
addit
sampl
exclud
pair
biopsi
gradabl
agrad
ax
n
gradabl
bgrade
bx
n
reject
identifi
total
elig
bal
sampl
patient
sampl
categor
follow
group
healthi
n
without
agrad
acr
lb
infect
agrad
acr
n
defin
agrad
greater
without
concurr
lb
without
infect
lb
n
defin
presenc
small
airway
inflamm
without
concurr
agrad
acr
infect
infect
n
defin
posit
cultur
potenti
pathogen
blind
clad
mortal
outcom
select
sampl
healthi
agrad
acr
lb
categori
addit
sampl
infect
group
rna
isol
addit
sampl
select
achiev
rel
balanc
across
follow
posttranspl
timefram
window
month
day
posttranspl
month
day
posttranspl
month
day
posttranspl
year
later
day
posttranspl
sampl
per
patient
includ
total
rna
isol
use
trizolchloroform
extract
resuspend
rnasefre
water
purifi
use
mirneasi
mini
kit
qiagen
inc
valencia
ca
rna
sampl
bioanalyz
agil
bioanalyz
agil
technolog
palo
alto
ca
sampl
exclud
rna
quantiti
low
ng
rna
integr
number
indic
sever
degrad
exclud
sampl
healthi
infect
lb
agrad
acr
insuffici
quantiti
n
degrad
rna
n
rna
sequenc
rnaseq
librari
prepar
clontech
smarter
strand
total
rnaseq
pico
kit
takara
bio
kusatsu
japan
key
step
includ
firststrand
synthesi
templat
switch
adapt
ligat
cleavag
ribosom
complementari
dna
polymeras
chain
reaction
amplif
librari
qualiti
evalu
use
agil
bioanalyz
sequenc
use
illumina
sr
run
illumina
san
diego
ca
demultiplex
illumina
v
initi
data
qualiti
check
illumina
sav
raw
read
map
latest
ucsc
transcript
set
use
version
gene
express
level
estim
use
rsem
bioconductor
packag
limma
linear
model
microarray
data
bioconductor
buffalo
ny
use
differenti
gene
express
analysi
normal
log
transform
count
rnaseq
data
avoid
overinterpret
includ
gene
least
read
per
million
map
read
least
sampl
limma
use
conjunct
voom
weigh
meanvari
relationship
logcount
need
accur
gener
linear
model
candid
list
differenti
express
gene
identifi
base
absolut
fold
chang
adjust
pvalu
limma
moder
ttest
p
function
annot
pathway
enrich
analysi
candid
probe
analyz
databas
annot
visual
integr
discoveri
david
process
pathway
select
base
adjust
pvalu
princip
compon
analysi
pca
use
visual
separ
group
unsupervis
hierarch
cluster
differenti
express
probe
done
appli
ward
minimum
varianc
criterion
linkag
method
euclidean
distanc
present
heatmap
construct
classif
model
first
split
subject
randomli
train
set
test
set
ratio
summar
subject
characterist
mean
standard
deviat
median
interquartil
rang
proport
characterist
compar
train
test
set
use
student
ttest
fisher
exact
chisquar
test
appropri
logist
regress
model
fit
use
recurs
featur
elimin
crossvalid
reduc
number
predictor
thu
achiev
parsimoni
model
model
fit
process
receiv
oper
characterist
area
curv
auc
metric
use
select
optim
model
threshold
select
base
model
perform
metric
train
set
valid
threshold
test
set
addit
cox
proport
hazard
model
curv
fit
cladfre
surviv
compar
group
diagnos
agrad
acr
biopsi
vs
clinic
condit
predict
acr
vs
predict
acr
use
genom
classifi
model
statist
analys
conduct
use
bioconductor
suit
packag
packag
caret
r
statist
softwar
environ
version
analys
cladfre
surviv
perform
use
graphpad
prism
version
window
graphpad
softwar
la
jolla
ca
www
graphpadcom
data
discuss
public
avail
mendeley
data
open
research
data
repositori
lung
transplant
recipi
elig
bal
sampl
final
studi
cohort
includ
uniqu
subject
bal
sampl
figur
clinic
characterist
elig
patient
includ
sampl
similar
final
studi
cohort
tabl
supplementari
materi
avail
onlin
wwwjhltonlin
org
design
select
sampl
enrich
later
time
point
posttranspl
like
histopatholog
posit
lb
agrad
acr
less
like
infect
diagnos
healthi
supplementari
tabl
onlin
addit
characterist
sampl
exclud
rna
quantiti
qualiti
similar
final
studi
cohort
except
measur
rna
quantiti
qualiti
supplementari
tabl
onlin
among
sampl
includ
final
studi
cohort
characterist
histopatholog
agrad
acr
similar
without
agrad
acr
biopsi
tabl
train
test
set
also
similar
supplementari
tabl
onlin
remov
transcript
low
read
count
across
sampl
transcript
remain
differenti
gene
express
analysi
identifi
gene
upregul
agrad
acr
figur
tabl
get
visual
impress
gene
express
patient
group
perform
pca
use
differenti
express
gene
pca
demonstr
consider
overlap
agrad
acr
sampl
categori
supplementari
figur
onlin
improv
modestli
focus
greater
acr
healthi
group
supplementari
figur
onlin
likewis
unsupervis
hierarch
cluster
analys
agrad
acr
sampl
tend
cluster
togeth
still
consider
misclassif
supplementari
figur
onlin
test
valid
biolog
relev
differenti
express
gene
compar
function
annot
pathway
map
use
david
bioinformat
resourc
comparison
biolog
process
categori
gene
ontolog
classif
indic
predomin
process
associ
agrad
acr
includ
immun
respons
adapt
immun
respons
tcell
receptor
tcr
signal
pathway
inflammatori
respons
tabl
similarli
kyoto
encyclopedia
gene
genom
pathway
significantli
enrich
gene
list
includ
tcr
signal
pathway
natur
killer
nk
cytotox
receptor
interact
allograft
reject
among
other
tabl
sought
develop
stabl
econom
classif
model
acut
reject
base
candid
list
differenti
express
target
gene
tabl
subject
randomli
split
train
set
test
set
elimin
redundantcorrel
gene
recurs
featur
elimin
develop
final
logist
regress
model
train
set
maxim
auc
requir
gene
thymocyt
high
mobil
group
box
protein
tox
steril
alpha
motif
interleukin
killer
cell
lectinlik
receptor
model
achiev
auc
train
set
figur
defin
classif
threshold
favor
specif
sensit
yield
classif
accuraci
figur
independ
test
set
sampl
model
exhibit
similar
perform
auc
figur
perform
classif
threshold
also
similar
train
set
specif
sensit
accuraci
figur
total
cohort
train
test
set
combin
proport
tbbx
agrad
acr
classifi
acr
genom
analysi
model
increas
increas
agrad
figur
similarli
ssar
case
classifi
acr
model
compar
agrad
acr
case
nonssar
p
furthermor
classif
acr
genom
analysi
also
associ
wors
cladfre
surviv
followup
biopsi
hazard
ratio
hr
clad
death
confid
interv
ci
figur
followup
extend
year
postbiopsi
cladfre
surviv
remain
wors
subject
classifi
acr
genom
analysi
supplementari
figur
onlin
comparison
agrad
acr
diagnos
tbbx
neither
associ
signific
differ
cladfre
surviv
hr
clad
death
ci
figur
followup
extend
year
postbiopsi
supplementari
figur
onlin
addit
effect
genom
classif
acr
cladfre
surviv
greatest
subset
patient
tbbx
neg
agrad
acr
hr
clad
death
ci
supplementari
figur
onlin
given
import
acr
modifi
risk
factor
clad
accur
diagnosi
remain
prioriti
lung
transplant
howev
current
gold
standard
requir
tbbx
drawback
includ
small
volum
tissu
sampl
lead
high
rate
suboptim
tissu
sampl
error
furthermor
even
biopsi
sampl
consid
adequ
interpret
fraught
high
interobserv
disagr
final
tbbx
associ
small
risk
major
complic
may
lead
morbid
even
mortal
rare
case
hypothes
gene
express
bal
cp
could
use
diagnos
acr
without
need
tbbx
furthermor
bal
cp
gene
express
might
improv
upon
tbbx
bal
sampl
larger
volum
lung
genom
classifi
would
remov
subject
proport
subject
clinic
categori
classifi
acut
cellular
reject
acr
genom
classifi
model
lb
lymphocyt
bronchiol
ssar
spirometr
signific
acut
reject
estim
chronic
lung
allograft
dysfunct
clad
free
surviv
year
follow
biopsi
comparison
cladfre
surviv
follow
bronchoscopi
procedur
patient
without
acut
cellular
reject
acr
histopatholog
b
comparison
cladfre
surviv
follow
bronchoscopi
procedur
patient
classifi
acr
acr
genom
classifi
model
bal
bronchoalveolar
lavag
patholog
interpret
current
studi
demonstr
proof
concept
gene
express
inform
acr
pathogenesi
also
suggest
potenti
util
diagnos
acr
risk
stratifi
develop
clad
better
tbbx
primari
find
agrad
acr
tbbx
associ
characterist
gene
express
profil
bal
cell
list
differenti
express
gene
enrich
biolog
process
pathway
integr
allograft
reject
instanc
kyoto
encyclopedia
gene
genom
tcr
signal
pathway
enrich
agrad
acr
includ
gene
lymphocytespecif
protein
tyrosin
kinas
lck
act
stabil
bind
tcr
peptidemajor
histocompat
complex
also
local
lck
complex
facilit
earli
signal
event
tcell
activ
also
previous
shown
bal
cp
gene
express
lck
associ
develop
clad
addit
receptor
interact
pathway
enrich
includ
interferon
gamma
find
corrobor
previou
work
show
protein
concentr
interferon
chemokin
bal
fluid
associ
agrad
acr
lung
injuri
pattern
well
clad
final
enrich
pathway
relat
cell
adhes
nk
cytotox
allograft
reject
add
addit
support
biolog
relev
bal
cp
gene
express
agrad
acr
express
profil
may
effici
simplifi
econom
classifi
model
exhibit
fair
perform
diagnost
biomark
histopatholog
agrad
acr
chose
threshold
model
priorit
specif
sensit
rational
aim
better
identifi
clinic
signific
acr
high
risk
progress
clad
recogn
welldescrib
shortcom
tbbx
surpris
model
reclassifi
case
histopatholog
agrad
acr
acr
case
histopatholog
agrad
acr
posit
acr
perform
genom
classifi
improv
increas
histopatholog
agrad
report
greater
observ
agreement
therefor
confid
acr
diagnosi
addit
classifi
model
indic
acr
case
ssar
strong
risk
factor
clad
given
import
acr
potenti
modifi
clad
risk
factor
intrigu
find
classif
indic
acr
also
discrimin
risk
cladfre
surviv
especi
year
follow
biopsi
wherea
histopatholog
diagnosi
agrad
acr
final
highest
incid
clad
death
year
biopsi
seen
case
histopatholog
neg
agrad
acr
genom
classifi
predict
acr
none
case
treat
reject
time
hypothes
corticosteroid
treatment
could
reduc
risk
clad
group
hypothesi
requir
prospect
evalu
clinic
trial
studi
corrobor
prior
smaller
observ
studi
gene
express
acr
although
studi
use
differ
method
specif
gene
associ
acr
differ
somewhat
function
relev
differenti
express
gene
remark
similar
across
studi
specif
increas
gene
express
relat
tcell
activ
cytotox
common
studi
similar
conclus
interest
especi
studi
reli
differ
platform
measur
gene
express
studi
use
rnaseq
wherea
prior
studi
use
microarray
studi
tcell
activ
high
correl
gene
express
profil
rnaseq
microarray
platform
use
set
sampl
howev
rnaseq
superior
detect
low
abund
transcript
demonstr
broader
dynam
rang
microarray
therefor
allow
detect
differenti
express
gene
furthermor
perform
rnaseq
allow
avoid
technic
issu
found
use
microarray
probe
eg
crosshybrid
nonspecif
hybrid
limit
detect
rang
individu
probe
addit
rnaseq
reli
predesign
detect
probe
thu
issu
associ
probe
redund
annot
simplifi
interpret
data
final
genom
classifi
model
includ
gene
tox
tox
shown
upregul
calcineurinmedi
tcr
signal
tcell
lineag
develop
includ
nk
regulatori
tcell
sublineag
shown
also
effect
tcell
develop
biolog
relev
allograft
reject
known
time
although
human
protein
atla
http
wwwproteinatlasorg
predict
intracellular
protein
broadli
express
lymphoid
tissu
especi
spleen
lymph
node
express
cell
nk
cell
play
role
acut
graftversushost
diseas
hematopoiet
cell
transplant
receptor
express
nk
cell
cytotox
lymphocyt
mediat
activ
nk
cell
costimul
cell
collect
model
consist
paradigm
acr
clad
pathobiolog
specif
acr
character
activ
immun
cell
includ
cell
cell
nk
cell
nk
cell
drive
cytotox
respons
allograft
injuri
eventu
lead
clad
futur
prospect
studi
test
whether
genom
classifi
lead
earlier
appropri
treatment
acr
intervent
might
reduc
clad
limit
inher
design
studi
examin
crosssect
select
sampl
lung
transplant
recipi
singl
center
would
valuabl
includ
longitudin
sampl
character
evolut
gene
express
acr
develop
clad
studi
determin
effect
treatment
gene
express
therefor
know
whether
knowledg
gene
express
impact
outcom
although
studi
includ
independ
train
test
cohort
patient
singl
center
futur
studi
would
benefit
inclus
extern
valid
cohort
reassur
fact
biolog
process
pathway
enrich
gene
list
consist
expect
also
acknowledg
sampl
select
inclus
inadequ
rnaseq
either
degrad
rna
low
rna
concentr
similar
rate
inadequ
tbbx
report
lung
transplant
recipi
howev
proport
inadequ
bal
sampl
rnaseq
could
probabl
reduc
nearli
use
rna
stabil
solut
rnaseq
librari
construct
kit
design
low
input
final
although
bal
cp
genom
classifi
test
could
reduc
complic
associ
tbbx
elimin
need
invas
bronchoscopi
unclear
whether
find
bal
cp
would
also
observ
peripher
blood
summari
show
bal
cp
gene
express
histopatholog
agrad
acr
enrich
immun
respons
includ
tcr
signal
cytokin
signal
cell
adhes
cytotox
gene
express
diagnos
acr
could
less
invas
altern
tbbx
fact
found
differenti
gene
express
simplifi
signatur
fair
perform
surrog
tbbx
potenti
greater
clinic
implic
studi
demonstr
proof
concept
bal
cp
gene
express
inform
pathogenesi
acr
risk
clad
multicent
studi
requir
establish
whether
bal
cp
gene
express
could
reduc
elimin
need
tbbx
diagnos
acr
none
author
financi
relationship
commerci
entiti
interest
subject
present
manuscript
conflict
interest
disclos
work
support
grant
nation
institut
allergi
infecti
diseas
